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Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder  
characterized by social-communication deficits and the presence of restricted 
interests and/or repetitive behaviors. There are currently no psychopharmacologi-
cal agents approved to treat core symptoms of ASD. As such, behavioral inter-
ventions are the most effective method for improving symptoms. In the current 
chapter, we propose that administering the neuropeptide oxytocin in conjunction 
with evidence-based behavioral interventions may lead to improved outcomes in 
social-communication for children with ASD. From a mechanistic perspective, 
we hypothesize that oxytocin may “prime” social reward circuitry in the brain, 
thereby allowing behavioral interventions designed to increase social motivation/
initiation to be more effective. Extant literature related to theories of ASD, oxy-
tocin administration in children with ASD, and behavioral intervention outcomes 
are reviewed, and considerations for individual characteristics (e.g., genetics, 
oxytocin availability, age, behavioral profile, etc.) that may affect efficacy are 
discussed.
Keywords: Autism spectrum disorder (ASD), Social Motivation, Oxytocin, 
Intervention, Reward, outcomes, neuroscience
1. Introduction
It is estimated that 1 in 59 children in the United States has a diagnosis of Autism 
Spectrum Disorder (ASD) [1], which is characterized by life-long social communi-
cation deficits and the presence of restricted interests and/or repetitive behaviors 
[2]. Though all individuals with ASD meet common diagnostic criteria, they display 
a wide spectrum of behavioral manifestations, thus producing a wide array of 
heterogeneous phenotypes. As such, a multitude of behavioral interventions exist 
to address common symptoms of ASD, many of which have been tailored to address 
the heterogeneity of the disorder. Behavioral interventions are currently one of the 
most effective methods for improving social-communication skills, as no medica-
tions have been approved to “treat” social communication behaviors in ASD.
In the current chapter, we propose that administering the neuropeptide oxytocin 
in conjunction with evidence-based behavioral interventions may lead to improved 
outcomes in social-communication for children with ASD. Specifically, we propose 
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that oxytocin administration may “prime” social reward circuitry in the brain, 
allowing behavioral interventions designed to increase social motivation/initiation 
to be more effective. This theoretical model draws from the following research: (1) 
the social motivation hypothesis of ASD, (2) animal and human literature related 
to oxytocin, (3) studies of oxytocin levels in children with ASD, (4) behavioral 
changes after oxytocin administration in children with ASD, (5) neural changes 
after oxytocin administration in children with ASD, and (6) neural changes after 
behavioral interventions in children with ASD.
Subsequent sections will briefly review these research areas. We propose that 
taken together, the aforementioned literature provides a theoretical basis for com-
bining oxytocin administration with behavioral interventions to improve social-
communicative outcomes for children with ASD.
2. Social motivation hypothesis of ASD
The social motivation hypothesis posits that early impairments in social atten-
tion (due to social stimuli being less rewarding for individuals with ASD compared 
to their neurotypical peers) set a series of negative developmental consequences in 
motion. Initial impairments in social attention--which often manifest as decreased 
orienting to one’s own name, diminished eye contact, and decreased social initia-
tions in early life--lead to fewer opportunities for social learning, which in turn lead 
to deficits in social communication, social skills, and social-cognitive development 
[3, 4]. The proposed neural mechanisms underlying the social motivation hypothe-
sis are the reward centers in the brain including the amygdala, ventral striatum, and 
orbito-frontal cortex [4]. Importantly, social motivation is thought to involve both 
oxytocin and the dopaminergic reward pathways [5, 6]. Given the hypothesized role 
of oxytocin in social motivation, it is not surprising that oxytocin has been consid-
ered as a potential mechanism for understanding social deficits in ASD--and that 
oxytocin administration has been considered as a potential therapeutic agent.
3. Oxytocin overview
Oxytocin is a neuropeptide produced in the hypothalamus [7]. Colloquially 
referred to as the “love hormone,” oxytocin has been implicated in the formation of 
pair bonds in a variety of species, including rats and prairie voles [8–10]. As such, 
oxytocin has been extensively studied and utilized for its effects on social cognition 
and prosocial behaviors [11–13]. It has been hypothesized that interactions between 
oxytocin and the dopaminergic reward system support social affiliative behaviors 
and social bonds [14]. Further evidence of the connection between oxytocin and 
the dopamine reward system comes from overlap in locations of receptor binding 
sites and neuronal fibers [15]. Furthermore, oxytocin cells in the hypothalamus 
have been found to express dopamine receptors [16]. Importantly for neurodevelop-
mental disorders such as ASD, oxytocin is developmentally regulated and its recep-
tors are malleable, particularly in response to parent-child interactions [17, 18].
In contrast to other conditions in which both behavioral and medical treat-
ments are supported by empirical evidence, no medication is currently approved to 
improve core symptoms of ASD. Although two pharmaceutical medications, risper-
idone and aripiprazole, have been approved by the Federal Drug Administration for 
use in ASD, they do not address core symptoms. Rather, they have been approved to 
treat ancillary symptoms of ASD, such as aggression and irritability [19]. Due to the 
lack of pharmacological interventions to address the core symptoms of ASD, there 
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has been a focus on compounds that directly address social communication symp-
toms. Given oxytocin’s role in prosocial behaviors, exogenous administration of the 
neuropeptide has been considered as a potential therapeutic agent in ASD.
3.1 Oxytocin levels in ASD
Modahl and colleagues [20, 21] were the first to provide evidence of reduced levels 
of oxytocin in children with ASD. Specifically, the authors found that compared to 
their neurotypical peers, oxytocin does not increase prior to the onset of puberty in 
individuals with ASD. This suggests that oxytocin is less available to individuals with 
ASD during development [21]. Our understanding of oxytocin in individuals with 
ASD has since been shaped by research that suggests deficits in oxytocin may reveal 
the pathogenesis of ASD. No known mechanistic pathway exists to form a substantial 
link between the neuropeptide and development of ASD, but studies support the idea 
that lower concentrations of oxytocin are strongly related to social impairments [22].
Early studies of the endocrine system have found that oxytocin release occurs 
differently in children with ASD compared to their neurotypical peers, suggesting 
that oxytocin may be disrupted early in development in children with ASD [23]. 
Oxytocin blood plasma levels increase throughout neurotypical development, while 
children with ASD exhibit lower levels of plasma oxytocin [24] that are stable over 
time [21]. Therefore, disruptions of the oxytocin system may possibly occur early in 
life in individuals with ASD, resulting in cascading consequences.
4. Oxytocin administration in children with ASD
4.1 Behavioral findings
To our knowledge, eight studies have been conducted to measure behavioral 
results of oxytocin administration for children with ASD [22, 24–33]. Though the 
current chapter focuses on children, see the meta-analysis by Ooi and colleagues 
[32] for a review of randomized control trials of oxytocin administration in both 
children and adults. See Table 1.
In 2010, Guastella and colleagues [25] completed a double-blind placebo-
controlled study with 16 adolescent boys with ASD (ages 12-19). 45 minutes after 
oxytocin (or placebo) administration, participants completed the Reading the Mind 
in the Eyes Task, or RMET [33]. Compared to placebo, oxytocin improved per-
formance on the REMET for 60% of participants. When the authors split REMET 
items into “easy” and “hard” categories, the effect of oxytocin was particularly 
significant for “easy” items. This was the first investigation of the results of oxyto-
cin administration to children/adolescents, and suggested that oxytocin improves 
emotion recognition in a group of males with ASD.
Tachibana and colleagues [26] measured behavioral changes associated with 
an open label (participants knew they were receiving oxytocin), single arm (no 
placebo condition) long-term oxytocin administration in 8 boys with ASD (ages 
10-14). Participants received intranasal oxytocin twice a day for approximately 7 
months. Oxytocin dosage was increased in a stepwise fashion every 2 months (from 
an initial dose of 8 IU to 24 IU). Outcome measures were scores on the Autism 
Diagnostic Observation Schedule—Generic (ADOS-G; [34]), Aberrant Behavior 
Checklist (ABC; [35]), and Child Behavior Checklist (CBCL; [36]). ADOS-G scores 
for items comprising the “communication,” and “social interaction” sub-scales and 
the sum of both sub-scales were significantly improved after oxytocin adminis-
tration. No change in ADOS-G scores related to play/imagination of restrictive/
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16 ASD (all male)
• Mage = 14.88 yrs., SDage 
= 2.42 yrs.
A single dose of oxytocin 
and a placebo nasal spray 
1 week apart.  
(a) OXT nasal spray and 
(b) placebo containing 
all ingredients except 
active oxytocin puff per 
nostril contained 3 IU. 
Older participants (aged 
16 –19, n = 5) received a 
dose of 24 IU (4 puffs per 
nostril, 3 IU per puff). 
Those aged 12 to 15 years 
n = 11 received 75% dose 
of the adult dose at 18 IU 
(3 puffs per nostril, 3 IU 
per puff).
Oxytocin improved 
performance on the REMET 
(particularly on “easy” 
items) compared to placebo.
Tachibana et 
al. [26]
Open label, single arm 
long-term design.
8 ASD (all male)
• Mage = 11.93 yrs., SDage 
= 1.32 yrs.
Intranasal oxytocin twice 
a day for approximately 
7 months; dosage was 
increased in a stepwise 
fashion every 2 months 
(from an initial dose of 
8 IU to 24 IU). Placebo 
was inserted between the 
dosing steps as a washout 
period. Concentration 
of OXT in the nasal 
spray was changed so 
that a total of 6 puffs/




social interaction scores on 
ADOS-G were significantly 




Single arm, open label 
design.
15 ASD (11 male, 4 
female)
• Mage = 13.8 yrs., SDage = 
2.4 yrs.
Twice per day (morning 
and night) for 12 weeks; 
24 IU total a day
Improvements on the 
following measures: ABC; 
SRS, BASC social skills and 
functional communication 
subscales, Let’s Face It! Skills 
Battery, Irony and Empathy 
Task, Strange Stories Task, 
CASI, RBS-R, and C-YBOCS





38 ASD (all male). 19 
in OXT group; 19 in 
placebo group
• OXT: Mage = 10.74 yrs., 
SDage = 2.38 yrs.
• PLACEBO: Mage = 11.79 





methyl parraben, propyl, 
parraben and purified 
water. Placebo contained 
all ingredients except 
the active oxytocin and 
mannitol. 5-day trial. 
Each nostril received a 12 
IU dose (6 IU per puff) 
for a total of 24 IU/day.
No significant benefit of 
oxytocin versus placebo on 
SSRS, SRS, or an emotion 
recognition task.
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50 ASD (all male); 26 
in OXT group, 24 in 
placebo
• OXT: Mage = 13.85 yrs., 
SDage = 1.54 yrs.
• PLACEBO: Mage = 14.00 
yrs., SDage = 2.04 yrs.
Intranasal oxytocin or 
placebo, 2 times per 
day for 8 weeks. Older 
participants (aged 16 
–19, n = 5 in each group) 
received a dose of 24 IU. 
Those aged 12 to 15 years 
received 75% of the adult 
dose at 18 IU.
No improvements related to 
oxytocin were observed on 
primary outcome measures 








31 ASD (27 male, 4 
female).15 in OXT then 
placebo group; 16 in 
placebo then OXT group
• OXT first: Mage = 5.7 
yrs., SDage = 1.5 yrs.
• PLACEBO first: Mage = 
6.7 yrs., SDage = 1.8 yrs.
Intranasal oxytocin or 
placebo twice per day for 
5 weeks, followed by a 4 
week wash-out period, 
and then received either 
oxytocin or placebo 
(whichever they did not 
receive in the first phase) 
twice per day for 5 weeks. 
24 IU total per day; 12 IU 
in morning and 12 IU at 
night.
Social-communication 
skills (SRS) improved 
significantly after oxytocin 
versus placebo. Ratings on 
the CGI were significantly 
better after oxytocin versus 
placebo.





32 ASD (27 males, 5 
females). 13 in OXT 
group; 14 in placebo 
group
• OXT: Mage = 9.35 yrs., 
SDage = 2.34 yrs.
• PLACEBO: Mage = 8.13 
yrs., SDage = 1.87 yrs.
Treatment group: 
Syntocinon nasal spray; 
Placebo group: placebo 
solution consisted of all 
the ingredients used in 
the active solution except 
the oxytocin compound. 
Participants’ parents then 
were provided with a 
4-week drug supply and 
were responsible for their 
child’s continued twice 
daily dosing (24 IU per 
dose, 4 IU per puff, 48 
IU/day) at home.
ASD participants who 
received oxytocin had 
greater improvements on 
the SRS compared to ASD 
participants who received 
the placebo. Pre-treatment 
plasma oxytocin negatively 
predicted the magnitude 
of improvement on the 
SRS (i.e., participants who 
had lower concentrations 
of oxytocin pre-treatment 
demonstrated the largest 









• Mage = 12.8 yrs., SDage 
= 3.4 yrs.
• 16 TD
• Mage = 13.2 yrs., SDage = 
3.2 yrs.
One nasal solution 
(oxytocin or placebo) 
on Visit 1 and the 
alternate solution on 
Visit 2. Participants 
16 years and older 
received 24 IU oxytocin 
(10 puffs alternating 
between nostrils 2.4 
IU). Participants aged 
12–15 years received 
7 puffs (16.8 IU), and 
participants aged 8–11 
years received 5 puffs (12 
IU total).
After nasal oxytocin was 
administered to ASD 
participants, differences 
in visual preference for 
structured/systemized 
images between ASD 
and TD participants was 
eliminated.
Table 1. 
Behavioral results of oxytocin administration in children with ASD.
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repetitive behaviors (RRBs) were observed. No significant changes were observed 
for the ABC or CBCL after oxytocin administration though some scores improved 
at a trend level. The authors note that oxytocin administration appeared to specifi-
cally affect social communication and interaction, but did not affect RRBs or play. 
However, the study was open label, single arm. Therefore, caution is needed when 
interpreting these findings.
Anagnostou and colleagues [27] administered intranasal oxytocin to 15 male 
and female adolescents (ages 10-17) twice per day for 12 weeks in a single arm, open 
label design. Participants completed a follow-up session 12 weeks after discontinu-
ation of oxytocin administration. Though the authors measured change on a variety 
of behavioral measures related to social function, social cognition, anxiety, and 
repetitive behaviors, the aim of the study was to measure the safety of varying 
dose levels of oxytocin in this population. Safety results suggested that .4 IU/kg 
twice per day for 12 weeks produced no serious or severe adverse events. Using the 
Clinical Global Improvement-Social (CGI), almost half of the sample were clas-
sified as “responders” at 12 weeks, and most responders at 12 weeks maintained 
improvements 12 weeks after the end of the study (e.g. 24 weeks from the begin-
ning of the study). At 12 weeks, significant improvements were observed for the 
following measures: ABC [35], Social Responsiveness Scale (SRS; [37]), Behavioral 
Assessment System for Children (BASC; [38]) social skills and functional com-
munication subscales, Let’s Face It! Skills Battery (LFI; [39]), Irony and Empathy 
Task [40], Strange Stories Task [41], Child and Adolescent Symptom Inventory 
(CASI; [42]), Repetitive Behavior Scale-Revised (RBS-R; [43]), Child Yale-Brown 
Obsessive-Compulsive Scale (C-YBOCS; [44]). At 24 weeks, significant improve-
ments were observed for the following measures: BASC functional communication 
T-Score, RMET [33]--difficult items, Irony and Empathy Task, and C-YBOCS. 
The authors note that not all children demonstrated behavioral improvements in 
response to oxytocin administration, and that more information is needed about 
individual differences in response to oxytocin. Nevertheless, a broad array of 
measures was, on average, shown to increase after oxytocin administration.
Dadds and colleagues [28] completed a 5-day double-blind, placebo controlled, 
randomized controlled trial with 38 boys with ASD (ages 7-16). This study is unique 
as it combined oxytocin administration with consecutive parent-child interac-
tion training sessions over a period of 4 days. The authors did follow-up testing 3 
months after the completion of the 5-day intervention. The parent-child interaction 
training consisted of emotion recognition training using the Mindreading (MR) 
program [45], and short video clips demonstrating successful client interactions 
(e.g. eye contact, body language, responsiveness). Outcomes included parent-child 
interaction tasks (free play, emotion talk, and an “I love you” task in which a parent 
expresses positive emotions and the child’s response is recorded), and parent-
questionnaire measures (Social Skills Rating Scale, or SSRS, [46]; SRS, [37]), and 
an emotion recognition task (UNSW Facial Emotion Task, [28]). Analysis of the 
parent-child interaction tasks, parent rating scales, and emotion recognition tasks 
indicated behavioral improvements over time in both the placebo and oxytocin 
groups, but no significant benefit of oxytocin versus placebo. We note that although 
this study combined oxytocin and behavioral intervention, the intervention was 
not one previously validated for improving core symptoms of ASD, and the study 
timeline was short (5 days).
Guastella and colleagues [29] completed a double-blind placebo-controlled trial 
with 50 male participants with ASD (ages 12-18). Participants received either placebo 
or oxytocin nasal spray twice a day for 8 weeks. Participants were assessed again 
3 months after completion of the study. Primary outcome measures were the SRS 
[37] and clinician ratings on the Clinical Global Impressions--Improvement scale 
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(CGI-Improvement). Secondary outcome measures included the Developmental 
Behaviour Checklist, or DBC [47] and Repetitive Behavior Scale-Revised, or RBS 
[43], RMET [33], the Diagnostic analysis of nonverbal accuracy, or DANVA [48], and 
Biological Motion [49]. No improvements related to oxytocin were observed on the 
primary or secondary outcome measures.
Yatawara and colleagues [30] completed a double-blind, randomized, placebo-
controlled crossover (A/B, B/A) design trial in 31 children with ASD (ages 3-8). 
Children received intranasal oxytocin or placebo twice per day for 5 weeks, com-
pleted a 4-week wash-out period, and then received either oxytocin or placebo 
(whichever they did not receive in the first phase) twice per day for 5 weeks. Primary 
outcome measures were scores on the SRS [37], and scores on the RBS-R [43]. 
Secondary outcome measures were changes in ADOS scores, scores on the DBC [50], 
clinician-rated clinical global impressions-improvement scale [51], and the Caregiver 
Strain Questionnaire [52]. Results indicated that parent-rated social-communication 
skills (SRS) improved significantly after oxytocin versus placebo. Ratings on the 
CGI were significantly better after oxytocin versus placebo. To our knowledge, this 
study includes the youngest sample of children with ASD to receive oxytocin versus 
placebo in a randomized, double-blind trial. This work provides behavioral evidence 
of symptom reduction in ASD in response to prolonged oxytocin administration.
Parker and colleagues [22] completed a double-blind, randomized, placebo-
controlled trial with 32 children with ASD (ages 6-12). Children received either 
intranasal oxytocin or placebo twice per day for 4 weeks. The primary outcome 
measure was scores on the SRS [37]. Secondary outcome measures included scores 
on the RBS-R [43] and Spence Children’s Anxiety Scale [53]. Additionally, authors 
measured plasma oxytocin concentrations both before and after participation in 
the trial, as well as expression of genes related to oxytocin receptors (Oxytocin 
Receptor Gene, OXTR, and Vasopressin Receptor 1a; V1AR). Results suggested that 
children who received oxytocin demonstrated greater improvements on the SRS 
compared to those receiving placebo. Additionally, pre-treatment plasma oxytocin 
negatively predicted the magnitude of improvement on the SRS. That is, individuals 
who had the lowest concentrations of oxytocin pre-treatment demonstrated the 
largest improvements. The authors hypothesized conflicting findings of previous 
oxytocin trials may be attributable to variability in pre-treatment concentrations of 
oxytocin. That is, previous trials did not measure pre-treatment oxytocin concen-
trations which may have reduced their ability to accurately measure improvement. 
When the authors did not include pre-treatment oxytocin, concentration find-
ings were non-significant. In fact, inclusion of these pre-treatment “biomarkers” 
improved the statistical models by 43%, which underscores the importance of 
measuring individual variability in pre-post measurement designs.
Strathearn and colleagues [31] completed a double-blind, placebo-controlled 
crossover study with 16 children with ASD and 16 neurotypical children (ages 
8-19). Participants completed an eye tracking paradigm on two occasions: once after 
receiving oxytocin and the other after receiving a placebo nasal spray. The authors 
measured participants’ eye gaze while viewing images that varied on how organized 
or structured they were. The authors’ primary focus was whether or not oxytocin 
affected eye gaze patterns when viewing stimuli that varied on levels of systemiza-
tion. Results demonstrated that after oxytocin administration, children and ado-
lescents with ASD displayed a decreased preference for highly systemized stimuli, 
whereas neurotypical children and adolescents displayed increased preference for 
systemized images. Overall, when participants received placebo, children and ado-
lescents with ASD displayed more of a preference for systemized stimuli compared 
to their neurotypical peers. After both groups received oxytocin this difference 
was no longer significant (e.g. participants with ASD looked more similar to their 
Oxytocin and Health
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neurotypical peers, and neurotypical children and teens looked more similar to their 
peers with ASD). The authors concluded that oxytocin administration may have 
differential effects on individuals with and without ASD, but that oxytocin appears 
to decrease preference for highly organized (e.g. systemized) stimuli in ASD.
Overall, studies of the behavioral effects of oxytocin in children in ASD are 
mixed, with some investigations observing significant behavioral changes [22, 
25–27, 30, 31], whereas others find no evidence for change as a function of oxytocin 
versus placebo administration [28, 29]. A likely explanation for these disparate find-
ings is outlined by Parker and colleagues [22]. The authors noted that measuring 
participant’s plasma oxytocin levels provided a critical “biomarker” for predicting a 
given individual’s response to oxytocin administration. Most studies do not measure 
oxytocin concentration prior to administration and therefore may miss individual 
differences which significantly impact outcomes. Parker and colleagues [22] noted 
that without the addition of pre-administration plasma oxytocin concentration into 
their predictive models, their results would have indicated no difference between 
oxytocin and placebo. When pre-administration oxytocin levels were included, 
their models were improved by 43%. This underscores why it is critical to consider 
biological differences in individuals prior to administration of oxytocin in order to 
more accurately understand variability within samples of children with ASD. When 
such individual differences are considered, behavioral effects of oxytocin may be 
more detectable, and/or may help us understand which children are most likely to 
benefit from oxytocin.
4.2 Neuroscience findings
To our knowledge, only 3 studies have investigated the effects of oxytocin on 
brain activity in children with ASD [54–56]; see [57] for a review. See Table 2.
Gordon and colleagues [54] used functional magnetic resonance imaging (fMRI) 
to measure brain activity after oxytocin versus placebo in 17 children and adolescents 
with ASD (ages 8-16.5) using a randomized, double-blind, crossover design. Forty-
five minutes after administration of either oxytocin or placebo, participants com-
pleted an fMRI emotion recognition task based on the RMET [33]. In a control fMRI 
condition, participants were asked to label the category of automobile presented in 
pictures. Findings suggested enhanced brain activity after oxytocin administration 
in brain areas hypothesized to be critical to reward (dorsal and ventral striatum), 
social attention and cognition (posterior cingulate, inferior parietal lobule, posterior 
superior temporal sulcus), and reasoning about mental states (medial prefrontal 
cortex). In addition, several brain regions were less active during nonsocial judge-
ments after oxytocin administration. Interestingly, the effect of oxytocin on brain 
activity in response to social judgements differed as a function of symptom severity. 
Children with ASD with less severe symptoms (measured with the SRS) exhibited 
more ‘typical’ brain activity after oxytocin administration compared to children with 
ASD with more severe symptoms. Taken together, the authors hypothesized that 
oxytocin may increase the reward value and/or salience of social stimuli for children 
with ASD while simultaneously decreasing the salience of nonsocial information.
Gordon and colleagues [55] employed a randomized, double-blind, 
placebo-controlled crossover design with 20 children with ASD (ages 8-16.5). 
Participants completed an fMRI scan twice: once receiving oxytocin and the 
other after receiving placebo nasal spray. The authors measured participants’ 
brain activity in response to two social perception tasks: a biological motion 
task and an affective voices task. The authors’ primary aim was to measure 
whether oxytocin increased brain activity in areas related to the reward 
system and the connections between reward and social brain regions (e.g. 
9
Priming the Pathway: Combining Oxytocin and Behavioral Intervention to Improve Outcomes…
DOI: http://dx.doi.org/10.5772/intechopen.96859







21 ASD (3 females; 18 males)
• Mage = 13.2 yrs., SDage = 2.7 
yrs.
Intranasally.
Older participants (16 – 19 yrs.) 
received a dose of 24 IU (4 puffs 
per nostril); 15 yr olds received 
18 IU (3 puffs per nostril);
Younger participants (7 - 11 
yrs.) received 12 IUs, (1 puff per 
nostril); or placebo.
Testing was repeated on 







Mind in the Eyes 
Test (RMET). 
Participants were 
instructed to label 
the mental state of 
each facial picture, 
or label the category 
of automobile 
images.
Social condition: Enhanced 
activity in the dorsal and 
ventral striatum, premotor 
cortex, posterior cingulate, 
inferior parietal lobule, and 
posterior STS in response 




20 ASD (3 females)
• Mage = 13.2 yrs., SDage = 2.8 
yrs.
Intranasally.
Older participants (16 – 19 yrs.) 
received a dose of 24 IU (4 puffs 
per nostril); 15 yr olds received 
18 IU (3 puffs per nostril).
Younger participants (7 - 11 
yrs.) received 12 IUs, (1 puff per 
nostril); or placebo.
Testing was repeated on 
consecutive study visits. Placebo 
or oxytocin was randomized at 
the first visit and participants 
received the opposite nasal 












motion) and listened 
to a vocal affect 
perception paradigm 
(angry voices and 
happy voices).
Biological motion condition: 
enhanced response in the 
right posterior superior 
temporal sulcus (pSTS) after 
oxytocin compared to placebo 
administration.
Negative vocal affect 
condition: Enhanced 
activation in right brainstem 
and right amygdala after 




28 ASD (2 females, 26 males)
• Mage = 13.4 yrs.,  
SDage = 2.4 yrs.
Intranasally.
3 puffs per nostril 
(Syntocinon), each puff 
contained 4 IU of oxytocin, 
for a total of 24 IU, or placebo 
containing the same inactive 
ingredients. Nostrils were 
alternated between puffs over 
the course of several minutes.
Two scan sessions were 
scheduled at least 72 hours 
apart from one another. Order 








task with nonsocial 
(money) or social 
rewards (smiling 
face).
Anticipation of nonsocial 
reward:
Increased activity in right 
nucleus accumbens (NAcc), 
right frontal pole, left ACC, 
left superior frontal cortex, 
bilateral orbital frontal cortex 
(OFC) after oxytocin versus 
placebo administration. 
Increased functional 
connectivity during nonsocial 
reward anticipation (between 
the right NAcc and the right 
FP) after oxytocin versus 
placebo.
Nonsocial reward outcome: 
Decreased frontostriatal 
functional connectivity 
between left ACC, bilateral 
postcentral gyrus, left inferior 
front gyrus, left precentral 
gyrus, and left medial frontal 
gyrus after oxytocin vs 
placebo administration.
Table 2. 
Neuroscience results after oxytocin administration in children with ASD.
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mesocorticolimbic pathways and communication between this pathway and 
socially-relevant brain regions) compared to placebo. Results were consistent 
with the author’s hypotheses: oxytocin enhanced neural responses to biologi-
cal versus random motion in the posterior superior temporal sulcus (pSTS), 
and in the amygdala and hippocampus in response to angry versus happy 
voices. Across both fMRI tasks, oxytocin increased neural connectivity both 
within reward regions and between the reward pathway and regions associated 
with social perception. The authors concluded that oxytocin administration 
appeared to enhance salience/reward of social stimuli (as measured in the bio-
logical motion task), but also increased the salience of negative social stimuli 
(as measured by the affective voices task).
Greene and colleagues [56] conducted a placebo-controlled, double-blind study 
with 28 children and adolescents with ASD (ages 10-17). Participants completed 
an fMRI incentive delay task on two occasions: once after receiving oxytocin, and 
once after receiving a placebo nasal spray. The fMRI task involved both social and 
non-social reward conditions so the authors could compare the effects of oxytocin 
versus placebo on brain activity related to both social and nonsocial rewards. 
Results demonstrated that compared to placebo, oxytocin increased brain activity 
in the caudate nucleus, left anterior cingulate cortex, frontal pole, insular cortex, 
and orbito-frontal cortex in the nonsocial reward versus social reward condition. 
Additionally, the authors found a positive relationship between symptom sever-
ity (measured using the SRS; [37]) and activation in the frontal pole and anterior 
cingulate during nonsocial reward anticipation, and between symptom severity 
and activation in the precentral gyrus and left caudate during nonsocial reward 
processing. Interestingly, these findings do not support the hypothesis that oxytocin 
selectively enhances reward-related brain activity to social stimuli, but rather may 
be associated with increased reward anticipation and processing for nonsocial 
stimuli. The authors hypothesize that reward-related effects of oxytocin may be 
sensitive to task-specific features, and noted that their findings strengthen the body 
of evidence that oxytocin acts on the brain’s reward system.
Taken together, these findings provide further evidence that intranasal oxytocin 
administration appears to act on the neural reward system. However, evidence is 
mixed regarding whether oxytocin specifically acts on the social reward system 
[54, 55] or the reward system more broadly [56]. It is likely that differences in 
neuroscience tasks, as well as differences in regions of interest, and participant 
sample characteristics may explain disparate findings. Importantly for our theoreti-
cal framework, intranasal oxytocin administration appears to impact the reward 
system in children with ASD. This provides an empirical basis for our hypothesis 
that combining a pharmacological agent with behavioral interventions that act on 
similar brain regions/networks may improve outcomes related to social initiation 
and communication.
5. Behavioral Interventions in ASD
Given the heterogeneous behavioral manifestations of ASD, it is not surpris-
ing that multiple behavioral interventions have been developed to improve social 
communication and decrease challenging behaviors [58–60]. Multiple systematic 
reviews have been published on the success of behavioral interventions for children 
with ASD (e.g. [61–64]), and an extensive review is beyond the scope of the current 
chapter. Of primary relevance to the current chapter are behavioral interventions 
designed to increase the salience, relevance, and reward value of social interactions 
in order to improve social-communicative symptoms.
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This section will briefly review two of these behavioral interventions, specifi-
cally the Early Start Denver Model (ESDM) and Pivotal Response Training (PRT) as 
both of these interventions are based on principles of Applied Behavioral Analysis 
(ABA) but emphasize naturalistic teaching strategies to promote generalization. 
Note, however, that there are other naturalistic interventions grounded in ABA 
principles (e.g. Incidental Teaching [65]; Reciprocal Imitation Training, or RIT 
[66, 67]; Parent-training programs, such as Project ImPACT [68]; Joint attention 
Interventions, such as JASPER [69, 70], and others).
5.1 Early start denver model (ESDM)
ESDM is an empirically validated, manualized intensive early intervention 
program designed for children between the ages of 1-4 [60, 71]. ESDM uses 
teaching strategies including: interpersonal exchange and positive affect, engage-
ment with real-world activities and materials, adult responsivity and sensitivity, 
and focus on both verbal and nonverbal communication. These strategies are 
grounded in ABA principles including operant conditioning, shaping, and chaining. 
Importantly, ESDM is not conceptualized as a behavioral intervention that must 
occur in a table-top or structured situation, nor is it a “one size fits all” approach. 
Each child’s program is individualized, and parent’s roles are emphasized. Parents 
are taught ESDM strategies and encouraged to utilize them during daily activities 
(e.g. feeding, bath time, play). In a 2010 randomized controlled trial, Dawson and 
colleagues compared the efficacy of ESDM versus treatment as usual (TAU) over 
a 2-year period [60]. Results found significant improvements in cognitive abilities 
in the ESDM group compared to TAU. These group differences appeared driven 
by improvements in both expressive and receptive language in the ESDM group. 
Additionally, significant group differences were observed in adaptive behaviors. 
Whereas children in the ESDM group remained steady in their adaptive behaviors 
across time, children in the TAU group exhibited lower scores across time when 
compared to their neurotypical peers. This difference appeared driven by increasing 
gaps between the TAU group and their neurotypical peers in a variety of adaptive 
skills, whereas children in the ESDM group displayed improvement in their com-
munication abilities. A recent meta-analysis corroborates the efficacy of ESDM in 
improving cognition and language for children with ASD [72].
5.2 Pivotal response training (PRT)
Pivotal response training (PRT), sometimes referred to as Pivotal Response 
Teaching or Pivotal Response Therapy, is a naturalistic behavior intervention 
based on principles of ABA. The underlying assumption of PRT is that children’s 
challenges can be improved with behavioral and environmental manipulations 
including reinforcement, contingencies, consequences, and extinction [73]. The 
term “pivotal” is important as it refers to pivotal behaviors that, when targeted, 
can lead to improvements in other areas of behavior not specifically targeted. 
The behaviors/function areas most commonly targeted in PRT are: motivation, 
initiation, responding to multiple cues, and self-management [74, 75]. To increase 
motivation, teaching strategies include: following the child’s lead, offering choices, 
providing clear opportunities for response, varying tasks, including both mainte-
nance and acquisition tasks, contingent and natural reinforcement, and reinforcing 
all attempts at target skills [73, 74]. Similar to ESDM, PRT emphasizes the impor-
tance of implementing the intervention in the child’s natural environment and the 
involvement of parents and other caregivers in the intervention [73]. Results of a 
systematic review indicate that PRT is largely effective at increasing self-initiation 
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and improving language, communication, and play skills in children with ASD 
[76]. A 2016 meta-analysis concluded that PRT is effective at teaching behaviors to 
children with ASD [77].
6. Neuroscience findings after behavioral intervention in ASD
Despite a wealth of research examining the behavioral utility of empirically-
based interventions for children with ASD, there is a relative paucity of literature 
utilizing neuroscience as an outcome measure or predictor of behavioral inter-
vention response (see [78] for a review). To our knowledge, seven studies have 
been published using neuroscience as either an outcome measure or predictor of 
response for an empirically supported behavioral intervention designed to help 
with core symptoms of ASD. See Table 3.
The first published paper using neuroscience as an outcome measure was 
Dawson and colleagues in 2012 [79]. 29 children with ASD (ages 48-77 months) 
participated in the study and were randomly assigned to either receive two years 
of ESDM intervention or two years of treatment as usual, TAU. Compared to 
toddlers in the community intervention, those who received ESDM demonstrated 
faster neural signatures of attention (the Nc ERP component) when viewing faces 
versus objects. Interestingly, when brain activity patterns of the two groups of 
toddlers with ASD were compared to brain activity of neurotypical (TD) toddlers, 
the ESDM and TD groups exhibited increased cortical activation when viewing 
faces versus objects, whereas toddlers in the TAU group evidenced more cortical 
activation when viewing objects vs. faces. The authors concluded that participation 
in ESDM appeared to lead to “normalization” of attention to faces. However, the 
authors did not include measures of brain activity prior to intervention, so they 
were unable to directly infer whether participation in ESDM significantly changed 
brain activity from pre to post intervention.
Voos and colleagues [80] used fMRI to measure brain activity in two five-year-
olds with ASD before and after four months of PRT. The fMRI paradigm involved 
watching point-light displays that were either attached to an adult who performed 
actions (e.g. biological motion) or scrambled light displays created with random 
selections of light points (scrambled motion). When measuring brain activity from 
brain areas implicated in ASD from previous research [81], the authors found that 
one participant had increased brain activity after intervention in the left fusiform 
gyrus and left dorsal prefrontal cortex, and the other participant had greater activa-
tion in the left ventrolateral prefrontal cortex, right posterior superior temporal sul-
cus, and fusiform gyrus. All of these brain regions have been previously implicated 
as relevant to processing social stimuli and biological motion. Despite the small 
sample size, the results suggest that PRT can increase brain activity in important 
regions associated with social stimuli.
Ventola and colleagues [82] also measured brain activity before and after 
participation in PRT. 10 children with ASD (aged 4-7) completed an fMRI bio-
logical motion task both before and after 16 weeks of PRT. 5 neurotypical children 
were tested twice (once at “baseline” and once 16 weeks later) but they did not 
receive PRT. Based on activity in the parietal temporal sulcus (pSTS) at baseline 
compared to neurotypical participants, children with ASD were separated into 
two groups: hypo- and hyper-active. Children with hypo-activation were hypoth-
esized to have decreased social motivation (evidenced by hypoactivity in the pSTS 
compared to neurotypical children), and children with hyper-activation were 
hypothesized to be hypersensitive to stimuli (evidenced by hyperactivity in the 
pSTS compared to neurotypical children). After PRT, children in the hypo-active 
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Dawson et al. 
[79]
15 ASD in ESDM group
• Mage = 54.1 mo., SDage 
= 4.9 mo.
14 ASD in the TAU 
group
• Mage = 54.1 mo., SDage 
= 7.8 mo.
17 TD participants
• Mage = 55.7 mo., SDage 
= 4.5 mo.






of faces and 
toys.
Faster Nc and increased cortical 
activation to faces vs. objects in 
the EDSM group. Faster Nc and 
increased cortical activation to 
objects vs. faces in the TAU group.
Voos et al. [80] 2 ASD (1 male, 1 
female), each 5 years old











Participant 1 (female): Increased 
activity in the fusiform gyrus (FG) 
and dorsolateral prefrontal cortex 
(dlPFC).
Participant 2 (male): Increased 
activity in the posterior superior 
temporal sulcus (pSTS), 
ventrolateral prefrontal cortex 
(vlPFC), and FG.
Ventola et al. [82] 10 ASD (8 male, 2 
female)
Hypoactive group (3 
male, 2 female):
• Mage = 5.3 yrs., SDage = 
.27 yrs.
Hyperactive group (5 
male):
• Mage = 5.66 yrs., SDage 
= 1.02 yrs.










Initially hypoactive group: 
increased activation in the ventral 
striatum (VS) and right posterior 
superior temporal sulcus (pSTS)
Initially hyperactive group: 
decreased activation in right 
pSTS, amygdala, thalamus, and 
hippocampus.
Van Hecke et al. 
[83]
28 ASD in the immediate 
treatment group (22 
male, 6 female)
• Mage = 14.1 yrs., SDage 
= 1.3 yrs.
29 ASD in the waitlist 
control (WLC) group 
(23 male, 6 female)
• Mage = 13.3 yrs., SDage 
= 1.7 yrs.
30 TD (28 male, 2 
female)








Immediate treatment: Increased 
left-dominant gamma asymmetry 
during resting state EEG after 
intervention vs. pre-intervention 




19 ASD (13 males, 6 
females)
• Mage = 5.87 yrs., SDage = 
1.09 yrs.









During biological motion, 
reduction in connectivity between 
the posterior cingulate cortex 
(PCC) and orbital frontal cortex 
and an increase in connectivity 
between the PCC and regions 




group had increased brain activity in the pSTS and ventral striatum when view-
ing biological motion, and decreased ventral striatum activity in response to 
scrambled motion. Children in the hyperactive group evidenced decreased brain 
activity in the pSTS, amygdala, thalamus, and hippocampus when viewing bio-
logical motion. The authors’ hypothesized that participation in PRT differentially 
affected brain activity of children depending on their baseline characteristics 
(e.g. children who displayed too little brain activity in response to social stimuli 
evidenced increased brain activity after intervention, whereas children who dis-
played too much brain activity in response to social stimuli evidenced decreased 
activity after intervention).
Van Hecke and colleagues [83] used electrophysiology (EEG) to measure brain 
activity before and after participation in a randomized control trial of the Program for 
the Education and Enrichment of Relational Skills (PEERS; [84, 85]) versus a waitlist 
control (WLC) condition. PEERS is an empirically validated, manualized program 
which focuses on making and keeping friends for adolescents with ASD [86].  





Yang et al. [89] 20 ASD (13 male, 7 
female)
• Mage = 5.90 yrs., SDage 
= 1.07 yrs.









Pre-intervention brain activity in 
the following areas while viewing 
biological motion predicted 
behavioral improvements on 
the SRS from pre- to post-
intervention. (1) social perception 
(fusiform gyrus, inferior temporal 
gyrus, middle temporal gyrus), 
(2) social attention (inferior 
parietal gyrus, superior parietal 
lobule), (3) emotion regulation 
and reward (orbitofrontal cortex, 
ventrolateral prefrontal cortex, 
anterior insula), and (4) social 
reward (putamen, pallidum, 
amygdala, hippocampus, ventral 
striatum)
Baker et al., [90] 7 ASD (6 male, 1 female)
• Mage = 13.88 yrs., SDage 
= 2.21 yrs.
7 TD (6 male, 1 female)








reward task with 
feedback that 






smile vs frown; 
arrow: upward 
vs downward).
Increased neural sensitivity to 
both social and nonsocial rewards 
(RewP amplitude) after versus 
before intervention.
Table 3. 
Neuroscience outcome measures of behavioral interventions in children with ASD.
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35 adolescents (13-14 years old) with ASD were randomly assigned to receive 
PEERS, 31 were randomly assigned to WLC, and 30 neurotypical (TD) adolescents 
were assessed prior to the intervention for comparison purposes. The authors mea-
sured brain activity patterns during “resting state” during which adolescents were 
instructed to focus on a fixation point for three minutes. Of particular interest was 
patterns of brain activity in the right versus left hemispheres as previous research 
suggests that individuals who have left-hemisphere dominance have higher approach 
motivation and positive affect compared to those with right-hemisphere dominance 
who are often characterized as withdrawn [87]. Prior to intervention, the two groups 
of teens with ASD evidenced less left-dominant asymmetry compared to the TD 
group. When comparing post-intervention brain activity of teens who received 
PEERS to brain activity in the TD group, differences in left-hemispheric dominance 
were no longer observed. Differences between the WLC group and the TD group were 
still observed after the 14-week intervention period (during which the WLC group 
did not receive intervention). These findings suggest that participation in PEERS 
(compared to a waitlist condition) significantly changed patterns of brain activity to 
be increasingly left-hemisphere dominant, which is more similar to patterns observed 
in neurotypical teens.
Venkataraman and colleagues [88] used a Bayesian probabilistic model to char-
acterize fMRI activity in 19 children with ASD (mean age 5.87 years) before and 
after 16 weeks of PRT. Similar to Ventola et al. [82], the fMRI paradigm involved 
watching two types of light displays: biological motion and scrambled motion. The 
probabilistic model allowed the authors to measure PRT-induced changes in neural 
connectivity between neural regions of interest. Results indicated both reduced 
connectivity between the posterior cingulate cortex (PCC) and orbitofrontal cortex 
and increased connectivity between the PCC and areas of the ventral occipital tem-
poral extrastriate cortex. These results are interesting given that the PCC is known 
for its role in social cognitive processes, the orbitofrontal cortex has been implicated 
in reward processes, and the ventral occipital and temporal cortices play a role 
in processing socially meaningful stimuli (including biological motion). These 
findings suggest that PRT causes a shift, in which connectivity between the PCC 
and orbitofrontal cortex is decreased while PCC and the ventral occipital-temporal 
cortex connection is strengthened.
Yang and colleagues [89] utilized fMRI as a pre-intervention predictor of 
intervention response in 20 children with ASD (mean age 5.90 years). The authors 
measured brain activity during a biological motion paradigm prior to 16 weeks 
of PRT. Results demonstrated that pre-intervention brain activity in areas impli-
cated in: (1) social perception (fusiform gyrus, inferior temporal gyrus, middle 
temporal gyrus), (2) social attention (inferior parietal gyrus, superior parietal 
lobule), (3) emotion regulation and reward (orbitofrontal cortex, ventrolateral 
prefrontal cortex, anterior insula), and (4) social reward (putamen, pallidum, 
amygdala, hippocampus, ventral striatum) while viewing biological motion 
predicted behavioral improvements on the SRS from pre- to post-intervention. 
For all 4 regions, greater levels of pre-intervention brain activity were associ-
ated with increased behavioral improvements from pre- to post- intervention. 
Results from this study suggest that neuroscience methods may be able to predict 
which children are most likely to benefit from a specific intervention, as well as 
underscoring the importance of brain regions associated with social perception, 
emotion regulation, and reward for understanding how interventions may affect 
brain circuitry in ASD.
Baker and colleagues [90] used event-related potentials (ERP) to measure brain 
response to reward in ASD adolescents before and after participation in the PEERS 
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program compared to a typically developing sample. Response to social and nonso-
cial rewards were measured using the reward-related positive component (RewP) 
in seven adolescents with ASD and seven TD adolescents, aged 10 to 17 years. Prior 
to intervention, patterns of reward-related brain activity (RewP mean amplitude) 
did not differ between groups. However, after intervention the ASD group demon-
strated an enhanced sensitivity to rewards, regardless of social or nonsocial condi-
tion, compared to the TD group. Additionally, ASD participants with less robust 
responses to social rewards prior to the start of the PEERS intervention demon-
strated the most gains in social behaviors (as measured via SRS-2 [91]; Social Skills 
Improvement System, [92]. Findings from this study suggest an enhancement of 
the neural response to rewards after teens with ASD receive training in social skills 
and additionally that teens with attenuated responses to social rewards may gain the 
most benefit from intervention.
Taken together, these seven studies provide evidence for two critical concepts: 
(1) Behavioral Intervention can significantly change patterns and/or magnitude 
of brain activity in response to social stimuli for children with ASD, and (2) 
Neuroscience may be able to predict individual levels of behavioral intervention 
response and could eventually be used to advance “precision medicine” (e.g. 
to predict who is most likely to benefit from a specific intervention). The first 
concept is central to our theoretical framework, as it suggests that participation 
in empirically based interventions changes brain activity in children with ASD-
-particularly in response to social stimuli and in brain areas/patterns of activity 
related to social perception and reward. Neural changes in the reward system and 
other areas of the “social brain” after interventions provides an empirical basis 
for our hypothesis that the addition of pharmacological compounds that enhance 
brain activity/responses in those same regions might lead to increased benefits for 
children with ASD.
7.  Current research combining oxytocin and behavioral interventions  
in ASD
Although there are no published studies (to our knowledge) that have conducted 
double-blind, placebo-controlled trials combining oxytocin administration with 
an empirically validated behavioral intervention in ASD, two trials are currently 
underway and recorded on ClinicalTrials.Gov (identifiers NCT02918864 and 
NCT03370510). We also note that a large-scale multi-site trial of the behavioral 
effects of oxytocin versus placebo is underway by the Study of Oxytocin in 
Autism to Improve Reciprocal Social Behaviors (SOARS-B; clinical trial identifier 
NCT01944046). One paper describing the rationale and methods for the trial has 
been published [93].
8. Does timing matter?
As noted above, we hypothesize that empirically based behavioral interventions 
designed to increase social-communication skills such as social initiation/motiva-
tion are more likely to be enhanced by oxytocin administration than interventions 
focused on other aspects of ASD (e.g. disruptive behaviors, anxiety). Such interven-
tions are typically aimed towards young children (i.e. ESDM was developed for chil-
dren ages 1-4) due to the targeted skills. We hypothesize that age is likely to play an 
important role in the efficacy of combining oxytocin with behavioral interventions 
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such that younger children are more likely to benefit due to: (a) Early interven-
tions in ASD often focus on improving social motivation and initiation, whereas 
interventions for older children are less likely to have such an emphasis. As oxytocin 
has been shown to affect the reward system, behavioral interventions designed to 
increase the reward value of social stimuli are likely to be the best candidates for 
this framework. (b) Increased neural plasticity in younger ages and the negative 
neuro-developmental sequelae described in the social motivation hypothesis. That 
is, young children have been hypothesized to benefit more from early interven-
tion for ASD compared to older children due to neural plasticity, and the social 
motivation hypothesis posits that decreased reward value of social stimuli early in 
life leads to a negative cascade of developmental consequences [5, 94]. It therefore 
seems likely that younger children are best positioned to benefit from combining 
behavioral intervention with oxytocin because early interventions may disrupt this 
negative developmental cascade and help children move back towards a typical 
trajectory. (c) Accumulating evidence that interventions for ASD are likely to be 
more effective if started earlier in life [94–96]. It is unclear, however, exactly how 
age will affect our theoretical model. Future research should pay close attention to 
how and if age is a predictor when measuring outcomes of combining oxytocin and 
behavioral intervention in ASD.
9. Conclusions
Taken together, considering extant research findings from behavioral and 
neural effects of oxytocin administration along with those on brain activity in 
response to behavioral interventions in children with ASD suggests that both oxy-
tocin and behavioral interventions lead to measurable changes in regions of the 
“social brain” and reward network. These findings, combined with those suggest-
ing that oxytocin administration may improve social-communication in children 
with ASD, provide the empirical basis of our hypothesis [57] that combining oxy-
tocin administration with behavioral interventions may improve outcomes related 
to social-communication. We hypothesize that the administration of oxytocin 
prior to each session of an intervention may “prime” the neural reward system to 
be maximally responsive to the behavioral skills taught during the intervention 
session. Due to the central role of the reward system in our theoretical model we 
hypothesize that this combined approach may be most effective for social-com-
municative skills requiring social motivation (e.g. social initiation/approach) and 
be maximally beneficial for young children. See Figure 1 for hypothesized neural 
mechanisms underlying the efficacy of combining interventions with oxytocin to 
improve outcomes.
It is important to note, however, that this approach is unlikely to be equally 
effective in all children with ASD. As with all interventions, there does not appear 
to be any “one size fits all” approach to help children with ASD. It will be critical 
to measure and characterize individual differences that may explain variability in 
treatment efficacy from biological (e.g. levels of oxytocin concentration in plasma/
saliva before and after oxytocin administration, genetic expression of candidate 
genes relevant for oxytocin; OXTR, VAP1, brain activity in response to social 
stimuli prior to oxytocin administration, age), behavioral (e.g. social communica-
tive symptom profile prior to oxytocin administration), and psychological (e.g. 
co-occurring diagnoses such as ADHD, anxiety, etc.) standpoints. Such individual 
differences will likely be central to our understanding of how, why, and for whom 




(1.1) Neuroscience Outcomes after Behavioral Intervention for Children with ASD. This figure depicts 
results from studies which measured brain activity before and after behavioral intervention. The brain 
areas highlighted in red indicate increased brain activity after behavioral intervention, whereas regions 
shown in blue indicate decreased brain activity after behavioral intervention. Results related to neural 
connectivity are shown with a dotted line. A. Dawson et al. [79], proposed neural generators of the Nc 
component (Reynolds & Richards, 2005) are highlighted (medial frontal gyrus, inferior frontal gyrus, 
anterior cingulate cortex); B. Voos et al. [80] ( fusiform gyrus, dorsolateral prefrontal cortex, posterior 
superior temporal sulcus (pSTS), ventrolateral prefrontal cortex (vlPFC)); C. Ventola et al. [82], ventral 
striatum (VS), pSTS, amygdala, thalamus, and hippocampus; D. Venkataraman et al. [88], reduction in 
connectivity between the posterior cingulate cortex (PCC) and orbital frontal cortex (OFC) and an increase 
in connectivity between the PCC and regions of ventral occipital temporal extrastriate cortex; E. Baker et 
al. [90], proposed neural generators of the RewP component (Carlson et al., 2011 & Proudfit, 2015) are 
highlighted (ventral striatum, dorsal striatum, OFC, medial frontal cortex); F*. Yang et al. [89], activity 
in the following pre-intervention brain areas were used to predict behavioral improvements: fusiform gyrus, 
inferior temporal gyrus, middle temporal gyrus, inferior parietal gyrus, superior parietal lobule, OFC, 
ventrolateral prefrontal cortex, anterior insula, putamen, pallidum, amygdala, hippocampus, ventral 
striatum. *This study used neuroscience measures prior to intervention as a predictor of intervention success, 
whereas the other studies used neuroscience measures pre- and post-intervention. (1.2) Neuroscience Results 
after Oxytocin Administration in Children with ASD. This figure depicts results from studies that have 
measured brain activity after oxytocin administration. Results related to neural connectivity are shown with a 
dotted line (red dotted line indicates increased connectivity, blue dotted line indicates decreased connectivity). 
G. Gordon et al., [55] (dorsal and ventral striatum, premotor cortex, posterior cingulate, pSTS); H. Gordon 
et al. [56] (pSTS, right amygdala, right brain stem); I. Greene et al., [56] (right nucleus accumbens (NAcc), 
right frontal pole (FP), left anterior cingulate cortex (ACC), left superior frontal cortex, bilateral OFC, 
functional connectivity during nonsocial reward anticipation (between the right NAcc and the right FP); 
frontostriatal functional connectivity between left ACC, bilateral postcentral gyrus, left inferior front gyrus, 
left precentral gyrus, and left medial frontal gyrus). (1.3) Neural Mechanisms Underlying the Proposed 
Additive Benefit of Combining Oxytocin with Behavioral Intervention. This figure depicts the proposed 
additive benefits of combining oxytocin administration with behavioral interventions for children with ASD. 
Brain regions that have been implicated in both behavioral intervention and oxytocin administration are 
labeled. We propose that oxytocin administration will “prime” neural structures related to reward and/or 
social information processing, which will make behavioral intervention sessions more effective.
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